Abstract
BackgroundEfficacy and safety of canakinumab (CAN) in frequently flaring difficult-to-treat gouty arthritis (GA) patients (pts) in whom NSAIDs and/or colchicine are contraindicated, not tolerated or ineffective has been published previously....
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have